Close Menu

Artemis Health

Anticipating that NGS will become a key clinical tool in coming years, several proteomics firms and researchers are investigating it as a platform for protein biomarker detection assays that use nucleotides as capture agents, hoping to take advantage of the technology's precision and multiplexing ability.

In Brief This Week is a Friday column containing news items that our readers may have missed during the week.

Using a sequencing method and proprietary algorithm based on technology licensed from Stephen Quake at Stanford University, the researchers correctly identified all trisomy 21 and trisomy 18 cases.

Caren Mason

A bioethicist argues that it is now time to start taking steps to consider how to handle ethical, social, and legal issues that loom over non-invasive prenatal genetic tests.

Companies developing DNA sequencing and related technologies, as well as firms working on sequencing-based genetic tests, were among almost 3,000 small biotechs who received a total of $1 billion in grants and tax credits under the QTDP program.

President Donald Trump might not approve the stricter standards the US Food and Drug Administration is developing for authorizing a SARS-CoV-2 vaccine, according to Politico.

Wired reports that Oxitec has now developed a genetically modified fall armyworm.

A large genetic study finds SARS-CoV-2 viruses with a certain variant are spreading more than others, according to the Washington Post.

In Nature this week: sister-chromatid-sensitive chromosome conformation capture approach, and more.